Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 1.00 |
| ▸ | CLK1 | P49759 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 3/20 | 1.00 |
| ▸ | CLK3 | P49761 | 3/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 1.00 |
| ▸ | MAP3K19 | Q56UN5 | 2/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 2/20 | 1.00 |
| ▸ | CSNK1G3 | Q9Y6M4 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | CLK2 | P49760 | 2/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977826 | 1.00 | DYRK1A (1.00) | DYRK1ACLK1HSD17B10CSNK1ECLK3 | |
| SCHEMBL18166902 | 0.90 | DYRK1A (0.81) | DYRK1ACLK1HSD17B10CSNK1ECLK3 | |
| SCHEMBL4667258 | 0.90 | DYRK1A (0.81) | DYRK1ACLK1HSD17B10CSNK1ECLK3 | |
| SCHEMBL4667255 | 0.90 | DYRK1A (0.81) | DYRK1ACLK1HSD17B10CSNK1ECLK3 | |
| SCHEMBL24718932 | 0.89 | DYRK1A (0.80) | DYRK1ACLK1HSD17B10CSNK1ECLK3 | |
| SCHEMBL4018924 | 0.89 | DYRK1A (0.80) | DYRK1ACLK1HSD17B10CSNK1ECLK3 | |
| SCHEMBL4018920 | 0.89 | DYRK1A (0.80) | DYRK1ACLK1HSD17B10CSNK1ECLK3 | |
| SCHEMBL24718937 | 0.89 | MAPT (1.00) | DYRK1ACLK1HSD17B10CSNK1ECLK3 | |
| SCHEMBL24718934 | 0.87 | DYRK1A (0.77) | DYRK1ACLK1HSD17B10CSNK1ECLK3 | |
| SCHEMBL24718933 | 0.86 | DYRK1A (0.76) | DYRK1ACLK1HSD17B10CSNK1ECLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3840749-B1 | COMPOUNDS FOR TREATING CARDIAC VALVE DISEASE | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2023-08-09 | — | — | EP | claimed |
| CN-107904201-B | Differentiation of human embryonic stem cells into the pancreatic endocrine lineage | 詹森生物科技公司 | 2021-11-16 | — | — | CN | claimed |
| US-20210228594-A1 | METHODS FOR TREATING CARDIAC VALVE DISEASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2021-07-29 | — | — | US | claimed |
| EP-2346988-B1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO THE PANCREATIC ENDOCRINE LINEAGE | JANSSEN BIOTECH INC (US) | 2017-05-31 | — | — | EP | claimed |
| US-20090042869-A1 | SIGNAL-DEPENDENT SPLICING OF TISSUE FACTOR PRE-mRNA IN PLATELET CELLS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-02-12 | — | — | US | claimed |
| US-12599608-B2 | Methods for treating cardiac valve disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-4316477-A1 | METHODS FOR TREATING CARDIAC VALVE DISEASE | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3840749-B1 | COMPOUNDS FOR TREATING CARDIAC VALVE DISEASE | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-107904201-B | Differentiation of human embryonic stem cells into the pancreatic endocrine lineage | 詹森生物科技公司 | 2021-11-16 | — | — | CN | disclosed |
| US-20210228594-A1 | METHODS FOR TREATING CARDIAC VALVE DISEASE | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE | 2021-07-29 | — | — | US | disclosed |
| US-20140099634-A1 | USE OF PRE-MRNA SPLICING IN PLATELET CELLS FOR THE DIAGNOSIS OF DISEASE | WEYRICH ANDREW S (US) | 2014-04-10 | — | — | US | disclosed |
| US-20100297621-A1 | USE OF PRE-MRNA SPLICING IN PLATELET CELLS FOR THE DIAGNOSIS OF DISEASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-7786151-B2 | Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction | KINOPHARMA, INC. (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20100112693-A1 | Differentiation of Human Embryonic Stem Cells | CENTOCOR ORTHO BIOTECH, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20090042869-A1 | SIGNAL-DEPENDENT SPLICING OF TISSUE FACTOR PRE-mRNA IN PLATELET CELLS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008156858-A2 | USE OF PRE-MRNA SPLICING IN PLATELET CELLS FOR THE DIAGNOSIS OF DISEASE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20070248590-A1 | Modulators of CDC2-like kinases (CLKS) and methods of use thereof | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20050171026-A1 | Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction | TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171026-A1 | Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction | SRPK3, PRKCA, PRKCB | DYRK1A 1932/4885CLK1 648/4885HSD17B10 2298/4885 |
| US-20210228594-A1 | METHODS FOR TREATING CARDIAC VALVE DISEASE | XDH, GUSB, CACNA1D | DYRK1A 4116/4885CLK1 2566/4885HSD17B10 792/4885 |
| US-12599608-B2 | Methods for treating cardiac valve disease | TNNT2, AGXT, CLCN2 | DYRK1A 1601/4885CLK1 917/4885HSD17B10 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.